
Toward the realization of a world where anyone, anytime, anywhere can enjoy medical-grade rapid testing.
The "Kansai Mirai Venture Award 'Mirai Way'" is a business plan contest for venture companies sponsored by Kansai Mirai Bank (Head office: Osaka City, Osaka; President: Kazuhiro Nishiyama) of the Resona Group.
The purpose of this event was to discover venture companies that challenge innovative technologies and business models and provide new value to the world, as well as advanced venture companies that will lead the region and create the future, and to support their growth and innovation creation.
Immunosense was one of 10 finalists selected from a total of 118 companies that applied to present at the finals, and was awarded the prestigious Grand Prix.
For more information, please see below.
Kansai Mirai Bank, Ltd. Press release on the results of the event:
https://www.resona-gr.co.jp/holdings/news/hd_c/download_c/files/20240614_1b.pdf?_ebx=5rp8146ity.1687770473.7w6n3yl&_gl=14sf22y_gcl_au*NDkyMjc1MjMyLjE3MTc5ODQ0MDk.
ImmunoSense will take this award as an opportunity to further accelerate its business development, and by realizing new POCT*1 (Point of Care Testing) products that are compact, easy to use, and highly accurate using its proprietary technology "GLEIA*2 (Gold-Linked Electrochemical Immunoassay)", ImmunoSense aims to create a world where anyone, anytime, anywhere can enjoy "medical grade rapid testing", We will strive to create a world where "medical grade rapid testing" can be enjoyed by anyone, anytime, anywhere.
1 About Immunosense's proprietary technology "GLEIA
Abbreviation for "Gold-Linked Electrochemical Immunoassay.
Immunoassay method developed by Dr. Eiichi Tamiya, Professor at the Institute of Scientific and Industrial Research, Osaka University, who is also the founder of ImmunoSense. In sandwich immunoassay, gold nanoparticles are used for antibody labeling, and the amount of antibody is electrochemically quantified using an electrode and potentiostat, thus achieving high detection sensitivity with a simple system configuration.
2 About POCT
Abbreviation for Point Of Care Testing (immediate clinical site testing).
A test performed at the patient's side in a clinical setting. Compared to other testing methods, POCT is characterized by a shorter time to obtain test results and quicker diagnosis and treatment of patients. Currently, advances in testing equipment and reagents have led to an increase in the number of test items that can be performed quickly and easily, and the POCT market is expanding.
Immunosense Overview
| name of company | Immunosense Inc. |
| Establishment | January 2018 |
| Location | 30602, 3F, Research Building, National Cardiovascular Center, 6-1 Kishibe Shinmachi, Suita, Osaka, Japan |
| representative | Representative Director Hirokazu Sugihara |
| Business Overview | Development of Immunosensor Devices for POCT |
| uniform resouce locator | https://immunosens.com/ |









